Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021498 | 0.86 | OPRD1 (0.47) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL617985 | 0.86 | OPRD1 (0.47) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| Hydrochloric Acid SCHEMBL619743 | 0.85 | OPRD1 (0.46) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL11253408 | 0.83 | OPRD1 (0.47) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL15086541 | 0.83 | OPRD1 (0.47) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL4355350 | 0.82 | OPRD1 (0.46) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL617209 | 0.75 | OPRD1 (0.44) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| Trifluoroacetic Acid SCHEMBL14916303 | 0.74 | TRPM8 (0.43) | KMT2AGRM2 | |
| SCHEMBL1134169 | 0.72 | OPRD1 (0.43) | OPRD1CYP2D6KCNH2TRPV1KMT2A | |
| SCHEMBL4343470 | 0.71 | KMT2A (0.62) | OPRD1CYP2D6KCNH2TRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | OPRD1 163/4885CYP2D6 965/4885KCNH2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.